ATP-binding cassette (ABC) transporters Activator

22 (R)-Hydroxycholesterol (Narthesterol) is a natural oxysterol, acting as a LXRα agonist that inhibits cancer cell proliferation. 22 (R)-Hydroxycholesterol activates LXRα-mediated upregulation of downstream ABCA1 expression, enhances apolipoprotein-dependent cholesterol efflux, reduces intracellular cholesterol content, and decreases the production of β-amyloid peptide. 22 (R)-Hydroxycholesterol induces the differentiation of human mesenchymal stem cells into functional dopaminergic neurons. 22 (R)-Hydroxycholesterol is applicable to research related to cancer, Alzheimer's disease, and Parkinson's disease.

ABC transporter modulator-2 (Compound I-200) is a ABC transporter expression modulator. ABC transporter modulator-2 upregulates the expression of wild-type ABCC6 with an EC₅₀ of <1 μM. ABC transporter modulator-2 upregulates the expression of wild-type ABCB4 with an EC₅₀ of <1 μM. ABC transporter modulator-2 upregulates the expression of wild-type ABCD2 with an EC₅₀ of <1 μM. ABC transporter modulator-2 upregulates the expression of the ABCA4^P1380L mutant with an EC₅₀ of <1 μM. ABC transporter modulator-2 can be used in the research of diseases associated with ABC transporter dysfunction.

ABC transporter modulator-1 (Compound I-5) is an ABC transporter expression enhancer. ABCC6 modulator-1 upregulates the expression of wild-type ABCC6, wild-type ABCB4, and ABCA4^P1380L mutant, with an EC₅₀ of <1 μM for all.

ABCC6 modulator-3 (Compound I-71) is a ABCC6 activator with an EC₅₀ < 1 μM. ABCC6 modulator-3 upregulates the expression of wild-type ABCC6. ABCC6 modulator-3 is used in research on diseases associated with ABC transporter dysfunction.

PPAR agonist 8 is an orally active pan-PPAR agonist, with K_D values of 0.576 μM, 2.06 μM and 1.45 μM for PPARα, PPARγ and PPARδ, respectively. PPAR agonist 8 upregulates the expression of ATP-binding cassette transporter A1 (ABCA1) and promotes cholesterol efflux. PPAR agonist 8 reduces plasma cholesterol levels, decreases cholesterol accumulation in the liver and cholesterol deposition in pancreatic islets, regulates glucose and lipid metabolism, and causes no side effects of weight gain and obesity. PPAR agonist 8 can be used in the research of type 2 diabetes, hepatic steatosis and pancreatic islet dysfunction.

SKLB06489 is a selective and orally active inhibitor of type I PRMT enzymes, with IC₅₀ values of 64.55 nM (PRMT1), 4.21 nM (PRMT6), and 51.27 nM (PRMT8). SKLB06489 inhibits cell proliferation, colony formation, DNA replication, and DNA damage repair in cancer cells. SKLB06489 induces G0/G1-phase cell cycle arrest and apoptosis in cancer cells. SKLB06489 enhances intracellular cholesterol efflux via ABCA1 and ABCG1 upregulation, disrupts cholesterol metabolic homeostasis, and suppresses tumor growth in subcutaneous xenograft models. SKLB06489 can be used for the research of triple-negative breast cancer (TNBC).

4010B-30 is a upregulator of apolipoprotein A-I (ApoA-I). 4010B-30 regulates ApoA-I gene expression through activation of PPARγ. 4010B-30 promotes cholesterol efflux and ABCA1 expression. 4010B-30 protects against atherosclerotic lesion development in ApoE^-/- mice.

22(R)-Hydroxycholesterol-d₇ (Narthesterol-d₇) is the deuterated-labeled 22(R)-Hydroxycholesterol (HY-116969). 22 (R)-Hydroxycholesterol (Narthesterol) is a natural oxysterol, acting as a LXRα agonist that inhibits cancer cell proliferation. 22 (R)-Hydroxycholesterol activates LXRα-mediated upregulation of downstream ABCA1 expression, enhances apolipoprotein-dependent cholesterol efflux, reduces intracellular cholesterol content, and decreases the production of β-amyloid peptide. 22 (R)-Hydroxycholesterol induces the differentiation of human mesenchymal stem cells into functional dopaminergic neurons. 22 (R)-Hydroxycholesterol is applicable to research related to cancer, Alzheimer's disease, and Parkinson's disease.